Pharma company's RMB30 million patent windfall emphasises need for greater Chinese IP value expertise
China’s desperate need for more IP strategy expertise is an issue that this blog has addressed on several occasions previously. A story IAM heard from a senior IP executive at a Chinese pharmaceutical manufacturer last week drives the point home.
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.